When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.

The Terry Burke Fund for Bladder Cancer Research at Vanderbilt-Ingram Cancer Center is supporting a range of discovery research aimed at improving outcomes for bladder cancer patients, and it is helping train the next generation of bladder cancer physician-scientists.

Vanderbilt-Ingram Cancer Center Ambassadors surpassed the $1 million mark with the awarding of the group’s latest research grants.

A team of Vanderbilt researchers mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer.

Some cancer patients receiving CAR-T infusions can now avoid hospital stays because of a telemedicine program launched by Vanderbilt-Ingram Cancer Center.

A Vanderbilt initiative to develop predictive imaging technologies that clinicians can use to better match patients with personalized care has received National Cancer Institute (NCI) funding.

Mia Levy, MD, PhD, director of Cancer Health Informatics and Strategy at Vanderbilt-Ingram Cancer Center (VICC) and Ingram Associate Professor of Cancer Research, has been named director of Rush University Cancer Center and Systems Vice President for Cancer Service at Rush University Medical Center in Chicago.